All In Biotech

Free tool

FAERS Monitor: Vyleesi (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210557 or its brand name (Vyleesi (Autoinjector), Bremelanotide Acetate). Reports on generic versions are filed under their own applications.

Reports

1,150

Serious

35

3% of reports

Hospitalization

6

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea494
  • drug ineffective237
  • headache170
  • vomiting127
  • off label use122
  • illness88
  • flushing83
  • adverse drug reaction65
  • dizziness51
  • feeling abnormal50
  • fatigue48
  • malaise43
  • condition aggravated40
  • cough38
  • pain34

Reports by year received

View as table
YearReports
201940
202050
202118
202245
2023150
2024155
2025341
2026351

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,009 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
illnessSignal8815.612.81,196
flushingSignal8314.912.11,070
adverse drug reactionSignal6513.210.5726
nauseaSignal49411.410.74,868
headacheSignal1705.04.3550
vomitingSignal1274.94.2404
feeling abnormalSignal503.82.9102
drug ineffectiveSignal2373.32.9400
off label useSignal1222.52.2118
coughSignal382.51.832
condition aggravatedSignal402.41.832
dizziness511.91.420
malaise431.81.315
fatigue481.10.91
pain341.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.